We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+38.45%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$617M
AUM Growth
+$270M
Cap. Flow
+$176M
Cap. Flow %
28.52%
Top 10 Hldgs %
38.27%
Holding
109
New
46
Increased
22
Reduced
16
Closed
21

Top Buys

1
ZBH icon
Zimmer Biomet
ZBH
+$15.9M
2
ABT icon
Abbott
ABT
+$12.9M
3
DBVT
DBV Technologies
DBVT
+$8.68M
4
CELG
Celgene Corp
CELG
+$8.12M
5
CYNO
Cynosure, Inc. Class A
CYNO
+$7.79M

Top Sells

1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.1M
2
MDT icon
Medtronic
MDT
+$8.68M
3
BLUE
bluebird bio
BLUE
+$6.15M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.68M
5
CNMD icon
CONMED
CNMD
+$5.52M

Sector Composition

1 Healthcare 51.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$49.7M 8.06%
750,000
+350,000
+88% +$21.7M
IBB icon
2
PUT
iShares Biotechnology ETF
IBB
$9.23B
$28.9M 4.69%
+300,000
New +$28.5M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$27.9M 4.53%
225,000
-125,000
-36% -$15.2M
SRPT icon
4
PUT
Sarepta Therapeutics
SRPT
$1.82B
$24.6M 3.98%
400,000
+100,000
+33% +$3.02M
SRPT icon
5
CALL
Sarepta Therapeutics
SRPT
$1.82B
$21.5M 3.49%
350,000
+250,000
+250% +$7.56M
BIIB icon
6
CALL
Biogen
BIIB
$30.4B
$20.3M 3.3%
+65,000
New +$19.3M
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$18M 2.92%
500,000
+50,000
+11% +$1.07M
ZBH icon
8
Zimmer Biomet
ZBH
$17.6B
$16.3M 2.64%
+128,750
New +$15.9M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$14.7M 2.38%
120,000
+30,000
+33% +$3.86M
NUVA
10
DELISTED
NuVasive, Inc.
NUVA
$14M 2.27%
210,000
+60,000
+40% +$3.82M
GWPH
11
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13.3M 2.15%
+100,000
New +$9.56M
ABT icon
12
Abbott
ABT
$175B
$12.7M 2.06%
+300,000
New +$12.9M
AERI
13
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$11.3M 1.84%
+300,000
New +$6.62M
SPNC
14
DELISTED
Spectranetics Corp
SPNC
$10.9M 1.77%
435,000
+60,000
+16% +$1.4M
BMY icon
15
CALL
Bristol-Myers Squibb
BMY
$124B
$10.8M 1.75%
+200,000
New +$12.8M
BSX icon
16
CALL
Boston Scientific
BSX
$65.4B
$10.7M 1.74%
450,000
+100,000
+29% +$2.39M
CELG
17
DELISTED
Celgene Corp
CELG
$10.5M 1.7%
100,000
+75,000
+300% +$8.12M
WMGI
18
DELISTED
Wright Medical Group Inc
WMGI
$10.4M 1.69%
425,000
+175,000
+70% +$4.03M
EW icon
19
Edwards Lifesciences
EW
$49.4B
$10.2M 1.66%
255,000
– –
PBYI icon
20
Puma Biotechnology
PBYI
$434M
$10.1M 1.63%
+150,000
New +$7.58M
BSX icon
21
Boston Scientific
BSX
$65.4B
$9.52M 1.54%
400,000
+75,000
+23% +$1.79M
MRK icon
22
CALL
Merck
MRK
$315B
$9.36M 1.52%
+157,200
New +$9.19M
ISEE
23
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.23M 1.5%
+200,000
New +$11.3M
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.82B
$9.21M 1.49%
150,000
-50,000
-25% -$1.51M
DBVT
25
DBV Technologies
DBVT
$870M
$9.08M 1.47%
+25,000
New +$8.68M
1
2 3 4 5

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Ghost Tree Capital held 109 positions worth $617M, up 78% from $346M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ghost Tree Capital deployed $176M of net new capital in Q3 2016, opening 46 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 128,750 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was bluebird bio, an estimated $6.15M trimmed.

  • Ghost Tree Capital's largest Q3 2016 buy was Zimmer Biomet: 128,750 shares worth $16.3M.
  • Ghost Tree Capital added most to Celgene Corp in Q3 2016, an estimated $8.12M increase.
  • Ghost Tree Capital's biggest Q3 2016 reduction was bluebird bio, cutting an estimated $6.15M.
  • Ghost Tree Capital fully exited IVERIC bio, Inc. Common Stock in Q3 2016, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 38% of its $617M portfolio in Q3 2016.
  • Ghost Tree Capital opened 46 new positions and closed 21 in Q3 2016.
  • Ghost Tree Capital's portfolio value rose 78% quarter-over-quarter to $617M.

Based on Ghost Tree Capital's 13F filing for Q3 2016, filed 14 Nov 2016.